Publicaciones en las que colabora con MARÍA DOLORES SANTOS BUELGA (37)

2022

  1. Aportación de la farmacocinética al tratamiento con fenobarbital: aplicación a algunos casos clínicos

    Farmajournal, Vol. 7, Núm. 1, pp. 83-91

  2. Diseño y elaboración de rúbricas para la autoevaluación y evaluación de las actividades

    I Jornada de Innovación Docente de las Universidades Públicas de Castilla y León

  3. Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients

    Pharmaceutics, Vol. 14, Núm. 4

2020

  1. Farmacocinética poblacional de fenitoína en pacientes adultos

    Farmajournal, Vol. 5, Núm. 2, pp. 15-26

  2. Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy

    European Journal of Pharmaceutical Sciences, Vol. 153

2019

  1. Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations

    Clinical Pharmacokinetics, Vol. 58, Núm. 6, pp. 767-780

2018

  1. Age as a Factor of Differentiation in Predictive Models of Valproic Acid Pharmacokinetics

    1st Global Congress of Pharmacy Faculties. Innovation in Pharmacy: Advances and Perspectives. September 24-28th, Salamanca, Spain 2018

  2. Electronic portfolio in a scientific methodology course at the Faculty of Pharmacyof the University of Salamanca

    IPAP 18 Innovations in Pharmacy: Advances and Perspectives

  3. Predicción “in silico” de la absorción de fármacos en pacientes celiacos

    Farmajournal, Vol. 3, Núm. 1, pp. 87-97

2017

  1. Modelos “in silico” para la predicción de la absorción de fármacos administrados por vía oral (SIMCYP®): estatinas

    Farmajournal, Vol. 2, Núm. 2, pp. 69-79

2016

  1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma

    British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527

2014

  1. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Tratado general de biofarmacia y farmacocinética: Volumen I: LADME. Análisis farmacocinético. Biodisponibilidad y bioequivalencia

    Síntesis

2011

  1. Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

2009

  1. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798

  2. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2008

  1. Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy

    Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489

2006

  1. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia

    Clinical Pharmacokinetics, Vol. 45, Núm. 12, pp. 1227-1238

2005

  1. Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941

  2. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941